Online inquiry

IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2600MR)

This product GTTS-WQ2600MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets MPL gene. The antibody can be applied in Chronic immune (idiopathic) thrombocytopenic purpurea (ITP) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005373.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4352
UniProt ID P40238
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ2600MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14839MR IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SGN-75
GTTS-WQ15628MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA VAY-736
GTTS-WQ12284MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ129MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 11F8
GTTS-WQ11357MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEDI-551
GTTS-WQ13424MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PRO132365
GTTS-WQ9690MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64304500
GTTS-WQ9734MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JR-141
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW